Zobrazeno 1 - 10
of 569
pro vyhledávání: '"N. Sabbagh"'
Publikováno v:
Neurology and Therapy, Vol 13, Iss 6, Pp 1541-1557 (2024)
Abstract As the prevalence of Alzheimer’s disease (AD) and its impact on healthcare systems increase, developing tools for accurate diagnosis and monitoring of disease progression is a priority. Recent technological advancements have allowed for th
Externí odkaz:
https://doaj.org/article/9c224d6e71524237be95fc28056caba9
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/235d44fcb4a64fba89f8c186629bc9ac
Publikováno v:
Neurology and Therapy, Vol 13, Iss 4, Pp 975-1013 (2024)
Abstract Progressive supranuclear palsy (PSP) is a neurodegenerative disorder resulting from the deposition of misfolded and neurotoxic forms of tau protein in specific areas of the midbrain, basal ganglia, and cortex. It is one of the most represent
Externí odkaz:
https://doaj.org/article/944c2a5236c04191939d2533133670e7
Autor:
Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer
Publikováno v:
Alzheimer’s Research & Therapy, Vol 16, Iss 1, Pp 1-12 (2024)
Abstract Background Alzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally. Lecanemab, an FDA-approved amyloid beta (Aβ)-directed antibody indicated for the treatment
Externí odkaz:
https://doaj.org/article/37323811cfca4e539a625fdbaee2b067
Autor:
Maurizio Bergamino, Anna Burke, Marwan N. Sabbagh, Richard J. Caselli, Leslie C. Baxter, Ashley M. Stokes
Publikováno v:
Frontiers in Aging Neuroscience, Vol 16 (2024)
IntroductionCognitive impairment (CI) due to Alzheimer’s disease (AD) encompasses a decline in cognitive abilities and can significantly impact an individual’s quality of life. Early detection and intervention are crucial in managing CI, both in
Externí odkaz:
https://doaj.org/article/620da2248c1248d49ec4f474e5a61eca
Autor:
Rita Sattler, Bryan J. Traynor, Janice Robertson, Ludo Van Den Bosch, Sami J. Barmada, Clive N. Svendsen, Matthew D. Disney, Tania F. Gendron, Philip C. Wong, Martin R. Turner, Adam Boxer, Suma Babu, Michael Benatar, Michael Kurnellas, Jonathan D. Rohrer, Christopher J. Donnelly, Lynette M. Bustos, Kendall Van Keuren-Jensen, Penny A. Dacks, Marwan N. Sabbagh, Attendees of the inaugural C9ORF72 FTD/ALS Summit
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1821-1843 (2023)
Abstract A summit held March 2023 in Scottsdale, Arizona (USA) focused on the intronic hexanucleotide expansion in the C9ORF72 gene and its relevance in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS; C9ORF72-FTD/ALS). The goal
Externí odkaz:
https://doaj.org/article/29cedee3ed35403a952639263a5b1ede
Autor:
Ana Sofía Ríos, Simón Oxenford, Clemens Neudorfer, Konstantin Butenko, Ningfei Li, Nanditha Rajamani, Alexandre Boutet, Gavin J. B. Elias, Jurgen Germann, Aaron Loh, Wissam Deeb, Fuyixue Wang, Kawin Setsompop, Bryan Salvato, Leonardo Brito de Almeida, Kelly D. Foote, Robert Amaral, Paul B. Rosenberg, David F. Tang-Wai, David A. Wolk, Anna D. Burke, Stephen Salloway, Marwan N. Sabbagh, M. Mallar Chakravarty, Gwenn S. Smith, Constantine G. Lyketsos, Michael S. Okun, William S. Anderson, Zoltan Mari, Francisco A. Ponce, Andres M. Lozano, Andreas Horn
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Deep brain stimulation has been investigated as a potential treatment for cognitive impairments in Alzheimer’s disease. Here the authors carry out post hoc analysis of multi-center cohorts to investigate the anatomical and functional correlates of
Externí odkaz:
https://doaj.org/article/44042e8fc7c347909735b26f535f79b5
Publikováno v:
Biomedicines, Vol 12, Iss 1, p 99 (2024)
Type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. Both T2DM and AD have been linked with increasing age,
Externí odkaz:
https://doaj.org/article/953e7ec9ca5c4d9daa03d492b4f5bcf2
Autor:
Marwan N. Sabbagh, Angela Taylor, Douglas Galasko, James E. Galvin, Jennifer G. Goldman, James B. Leverenz, Kathleen L. Poston, Bradley F. Boeve, David J. Irwin, Joseph F. Quinn
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 9, Iss 1, Pp n/a-n/a (2023)
Abstract The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Cli
Externí odkaz:
https://doaj.org/article/4e846c116fef4bab9db52b268fd87230
Autor:
Gregory D. Scott, Moriah R. Arnold, Thomas G. Beach, Christopher H. Gibbons, Anumantha G. Kanthasamy, Russell M. Lebovitz, Afina W. Lemstra, Leslie M. Shaw, Charlotte E. Teunissen, Henrik Zetterberg, Angela S. Taylor, Todd C. Graham, Bradley F. Boeve, Stephen N. Gomperts, Neill R. Graff-Radford, Charbel Moussa, Kathleen L. Poston, Liana S. Rosenthal, Marwan N. Sabbagh, Ryan R. Walsh, Miriam T. Weber, Melissa J. Armstrong, Jee A. Bang, Andrea C. Bozoki, Kimiko Domoto-Reilly, John E. Duda, Jori E. Fleisher, Douglas R. Galasko, James E. Galvin, Jennifer G. Goldman, Samantha K. Holden, Lawrence S. Honig, Daniel E. Huddleston, James B. Leverenz, Irene Litvan, Carol A. Manning, Karen S. Marder, Alexander Y. Pantelyat, Victoria S. Pelak, Douglas W. Scharre, Sharon J. Sha, Holly A. Shill, Zoltan Mari, Joseph F. Quinn, David J. Irwin
Publikováno v:
Frontiers in Neurology, Vol 12 (2022)
The Lewy Body Dementia Association (LBDA) held a virtual event, the LBDA Biofluid/Tissue Biomarker Symposium, on January 25, 2021, to present advances in biomarkers for Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLBs) and Par
Externí odkaz:
https://doaj.org/article/e84d47ecb7c4440da3c49a05adb2450e